What is Sampling Human?
Sampling Human, Inc. operates at the intersection of synthetic biology and clinical diagnostics. The company is the architect of the Diagnostics On Target (DOT) platform, a next-generation technology designed to bridge the gap between complex single-cell data and actionable clinical practice. By engineering accessible reagent kits for liquid biopsy, the firm effectively bypasses the performance constraints typically associated with traditional flow cytometry. This approach not only elevates the sensitivity of disease detection but also significantly accelerates the speed of assay results, positioning the company as a disruptive force in early-stage disease monitoring and treatment optimization.
How much funding has Sampling Human raised?
Sampling Human has raised a total of $2M across 1 funding round:
Other Financing Round
$2M
Other Financing Round (2022): $2M with participation from i&i Biotech Fund, Formic Ventures, and Longevitytech.Fund
Key Investors in Sampling Human
i&i Biotech Fund
A venture capital firm specializing in early-stage biotech and life sciences, focusing on translating academic research into commercial diagnostic and therapeutic solutions.
Formic Ventures
An investment firm that provides strategic backing to high-growth technology companies, often focusing on innovative hardware and software solutions that disrupt traditional industry verticals.
Longevitytech.Fund
LogevityTech.fund is focused on global investments in technologies that aim to extend healthy lifespans. The company seeks to support innovations that contribute to longevity and improved health outcomes.
What's next for Sampling Human?
With this major strategic investment, Sampling Human is poised to accelerate the commercial deployment of its DOT platform. The company's roadmap likely involves expanding its manufacturing capacity and deepening its clinical validation studies to ensure broader adoption in hospital and laboratory settings. By leveraging its unique method of harnessing living cells to analyze biological samples, the firm is well-positioned to redefine the standards for liquid biopsy. Future growth will likely focus on strategic partnerships with healthcare providers to integrate these high-sensitivity tools into routine clinical workflows, ultimately improving patient outcomes through earlier and more precise diagnostic interventions.
See full Sampling Human company page
